Aneuploidy may also occur within a group of closely related species.

Several studies have suggested that polar body screening for aneuploidy may not be optimal.

For other cancers, more work is warranted to identify the causes of aneuploidy.

There are three ways that aneuploidy can occur.

Therefore the molecular processes that lead to aneuploidy are targets for the development of cancer drugs.

Background Aneuploidy is a common feature of cancer.

Aneuploidy is the state of not having euploidy.

Therefore, two effective approaches have been developed that can be used for the detection of fetal aneuploidy.

Aneuploidy is the characteristic of having an abnormal number of chromosomes.

Together with the progression, more and more aneuploidy occurs.

If it is not corrected, both chromatids will end in the same daughter cell, generating aneuploidy.

Polyploidy and aneuploidy are common phenomena in cancer cells.

Deregulation of these proteins can lead to multiple centrosome formation and aneuploidy.

Aneuploidy occurs during cell division when the chromosomes do not separate properly between the two cells.

Aneuploidy is more common with advanced reproductive age reflecting decreased germ cell quality.

Aneuploidy is consistently observed in virtually all cancers.

Aneuploidy is a trait of many cancerous tumors.

A substance's aneugenicity reflects its ability to induce aneuploidy.

Thus, point mutations, copy number variations, loss of heterozygosity or aneuploidy can be detected.

Aneuploidy may be a cause of a random spontaneous as well as recurrent pregnancy loss.

Agents capable of causing aneuploidy are called aneuploidogens.

It can be used for gene mapping, detecting aneuploidy, locating tumours etc.

A trisomy is a type of aneuploidy (an abnormal number of chromosomes).

However, the most obvious models for the deleterious effects of aneuploidy should instead depend on the total number of genes.